Akari Therapeutics Plc Sponsored ADR Stock News

Patent filing covers PH1 payload's unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism

Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September

Video webcast now available  here

AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models

AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027

Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload platform Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody d...

Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform

TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research collaboration with Whitehawk Therapeutics, a clinical-stage oncology therapeutics company applying advanced technologies to established tumor...